Skip to main content
Equibles

Matthew Roden

CEO

Aktis Oncology, Inc. (AKTS)

Equibles does not estimate personal net worth.

Get an email with a short summary when Aktis Oncology, Inc. publishes a filing, an earnings call transcript or a press release.

Get AKTS alerts

About Matthew Roden

Matthew Roden is recorded as CEO at Aktis Oncology, Inc. (AKTS). Matthew Roden has spoken on 9 investor events across 1 company, most recently for Aktis Oncology, Inc. on September 16, 2026. Aktis Oncology, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Aktis Oncology, Inc. includes Glenn Gormley (Board Member).

Matthew Roden on recent calls

“And also thank you to everybody here in the audience for your interest in tracking our story. ACKIS Oncology is a clinical stage oncology company focused on developing a novel set of radiopharmaceuticals or radioligam therapies.”
CEO, Morgan Stanley 24th Annual Global Healthcare Conference ·
“It's a pleasure to be here and to present the story of Atkis Oncology. We are a targeted radiopharmaceutical company looking to transform the space by opening up the field of radiopharmaceuticals for patients who have no access to radiopharmaceuticals as of yet.”
CEO, Jefferies Global Healthcare Conference ·
“It's a pleasure to be here and to present the story of Atkis Oncology. We are a targeted radiopharmaceutical company looking to transform the space by opening it up the field of radiopharmaceuticals for patients who have no access to radiopharmaceuticals as of yet.”
CEO, JEFFERIES GLOBAL HEALTHCARE CONFERENCE ·
“Thank you, Alex, and thank you, everyone, for joining today's call, which is in reference to our May 21st press release summarizing the two posters on AKY 2519 to be presented at the ASCO annual meeting on May 30th.”
CEO, Aktis Oncology: AKY-2519 Clinical Imaging and Dosimetry Data Conference Call ·
“Thank you, Alex, and thank you, everyone, for joining today's call, which is in reference to our May 21st press release summarizing the two posters on AKY 2519 to be presented at the ASCO annual meeting on May 30th.”
CEO, AKTIS ONCOLOGY: AKY-2519 CLINICAL IMAGING AND DOSIMETRY DATA CONFERENCE CALL ·

Affiliation history

Company network

Leadership on record at Aktis Oncology, Inc.

Recent activity